Turkey probes Israeli pharmaceutical company Teva over claims it blocked rivals in drug market
The Turkish investigation was opened against Teva International, its subsidiary Teva Europe, and its subsidiary in Turkey to determine whether the law was violated.
Turkey's Competition Authority has initiated an investigation into Israeli pharmaceutical company Teva, alleging the company may have violated local laws and hindered competitors in the Turkish pharmaceutical market. According to Turkey's state-run news agency Anadolu, the Competition Authority conducted a preliminary investigation into Teva's actions in the generic drug sector, including potential misuse of patent procedures and misleading information given to health authorities in Ankara regarding the safety and efficacy of certain products.
The investigation was launched against Teva International, its subsidiary Teva Europe, and Teva's subsidiary in Turkey. The authorities are probing whether Teva's actions restricted competition and manipulated patent applications for production methods and drug dosages. This investigation does not yet result in any sanctions being imposed on Teva.
Teva is one of the few Israeli companies still operating in Turkey due to the trade embargo on Israel. The company's headquarters are located in Istanbul, and it also runs commercial activities for marketing drugs, along with collaborations with local organizations to enhance access to medical care. Another Israeli company, ICL (previously known as Israel Chemicals), remains present in Turkey as part of its global operations.
Lastly, Netafim, an irrigation company, is a notable presence in Turkey, owned by Mexican corporation Orbia and Kibbutz Hatzerim.
Written by urgent.news from Jerusalem Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
